Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 857

Advocates’ Guide for PPPR

If you’re having trouble making sense of all of the initiatives around pandemic prevention, preparedness, and response (PPPR) this year, don’t worry—you’re not alone! This Advocates Guide provides a reference for the relevant information all in one place. The contents explain the major initiatives, key dates for involvement, how to get involved and make sure your priorities are heard by decision makers.

Prevention Option:

June 2024


PxPulse: The Advocacy Chronicles with SMUG’s Allan Mwasa

In this episode, we’re speaking with Nsubuga Allan Mwasa, a Ugandan activist, clinical psychologist and an advocate for mental health and LGBTQ+ rights. Allan serves as Strategic Initiatives Manager at Sexual Minorities Uganda (SMUG), which has been at the forefront of the fight for LGBTQ rights.

Prevention Option:

June 2024


Announcing the Next Class of Advocacy Navigators

We are thrilled to announce AVAC’s 3rd class of Advocacy Navigators! This group of 12 emerging advocates from nine countries was selected from 100s of interested applicants. They will be paired with six mentors, seasoned advocates who are alumni of AVAC’s Advocacy Fellows program. These mentors provide support and guidance as the Navigators strengthen and expand their skills in HIV prevention advocacy.

June 2024


Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

May 2024


Tracking PrEP Rollout & Learning Lessons

Over the last two years, BioPIC—a project led by AVAC with support from the Gates Foundation—has been gathering and sharing evidence on these critical lessons to ensure the next generation of HIV prevention products reaches everyone who needs and wants them with much greater speed and equity.

May 2024


What’s Next for the Pandemic Accord? A civil society and communities perspective

This side event, co-sponsored with Care and Frontline AIDS, was part of the World Health Assembly and featured expert panelists discussing what’s promising in the Pandemic Accord, what we expect from governments, and what’s missing for successful implementation. Selected panelists came from different health areas but all have experience in pandemic prevention, preparedness, and response.

May 2024


New Product Introduction Update

A graphic showing ongoing studies of injectable cabotegravir and the dapivirine vaginal ring in eastern and southern Africa.

May 2024


Top Vaccines Funders

Total US dollars invested by each of the top 10 global funders of vaccine research in 2022.

May 2024


PxWire Volume 14, Issue No. 2

The latest issue presents new research on the effectiveness of oral PrEP in cisgender women, new injectable cabotegravir approvals and rollout, and much more!

Prevention Option:

May 2024


An Overview of Lenacapavir for PrEP Trials

The PURPOSE efficacy trials are expected to report results later this year or in early 2025. If the six-monthly injectable lenacapavir demonstrates safety and efficacy, it will be the next long-acting injectable PrEP option to enter the market—and it is not too early to plan.

Prevention Option:

May 2024


showing 1-10 of 857